These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 11835924)

  • 21. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study.
    Emery P; Koncz T; Pan S; Lowry S
    Clin Ther; 2008 Jan; 30(1):70-83. PubMed ID: 18343244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
    Dong YH; Chang CH; Wu LC; Hwang JS; Toh S
    Br J Clin Pharmacol; 2018 May; 84(5):1045-1056. PubMed ID: 29468706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
    McGettigan P; Henry D
    JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
    Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
    Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
    Clemett D; Goa KL
    Drugs; 2000 Apr; 59(4):957-80. PubMed ID: 10804043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
    Solomon DH; Husni ME; Wolski KE; Wisniewski LM; Borer JS; Graham DY; Libby P; Lincoff AM; Lüscher TF; Menon V; Yeomans ND; Wang Q; Bao W; Berger MF; Nissen SE;
    Arthritis Rheumatol; 2018 Apr; 70(4):537-546. PubMed ID: 29266879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
    Soni P; Shell B; Cawkwell G; Li C; Ma H
    Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
    Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
    Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
    Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS.
    Prescrire Int; 2003 Jun; 12(65):89-90. PubMed ID: 12825570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
    Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
    Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.